8-K
filed February 11, 2026, 6:59 PM ET
ticker INSP
CIK 0001609550
earnings
confidence high
sentiment negative
materiality 0.85
Inspire Q4 rev $269M (+12%), EPS $4.66; FY26 outlook lowered on coding change
Inspire Medical Systems, Inc.
2025-FY EPS reported
$4.89
revenue$911,981,000
- Q4 revenue $269.1M (+12%); GAAP diluted EPS $4.66; adjusted EPS $1.65.
- Full year revenue $912M (+14%); operating cash flow $117M; share repurchases $175M.
- FY2026 revenue guidance revised to $950M-$1.0B (4-10% growth); adjusted EPS $1.85-$2.35.
- Inspire V procedure coding changed to CPT 64582 with -52 modifier, reducing physician fees; company disappointed.
- Board proposes declassification and removal of for-cause removal; effective upon shareholder approval at 2026 annual meeting.
Machine-readable event card
- schema_version
- secwatch.filing_event.v1
- accession
- 0001609550-26-000012
- form_type
- 8-K
- ticker
- INSP
- cik
- 0001609550
- company_name
- Inspire Medical Systems, Inc.
- filed_at
- 2026-02-11T23:59:59+00:00
- discovered_at
- 2026-05-14T18:02:35.635740+00:00
- generated_at
- 2026-05-16T03:18:51.383704+00:00
- sec_items
- ["2.02", "5.03", "7.01", "9.01"]
- event_type
- earnings
- sentiment
- negative
- materiality_score
- 0.85
- calibrated_materiality_score
- 0.85
- confidence
- high
- secwatch_canonical_url
- https://secwatch.observer/filing/0001609550-26-000012
- json_url
- https://secwatch.observer/filing/0001609550-26-000012.json
- markdown_url
- https://secwatch.observer/filing/0001609550-26-000012.md
- text_url
- https://secwatch.observer/filing/0001609550-26-000012.txt
- edgar_index_url
- https://www.sec.gov/Archives/edgar/data/1609550/000160955026000012/0001609550-26-000012-index.htm
- edgar_primary_document_url
- https://www.sec.gov/Archives/edgar/data/1609550/000160955026000012/insp-20260205.htm
- generated_by_model
- deepseek-v4-flash:cloud@v2
- review_status
- machine_generated
- human_reviewed
- false
- corrected
- false
- correction_note
- null
- correction_timestamp
- null
- superseded_by
- null
Comparable filings
TKNO
Teknova Q1 revenue $11.1M (+13% YoY); reaffirms FY 2026 guidance $42-44M
Alpha Teknova, Inc.
May 6, 2026, 7:59 PM ET
earnings
Items 2.02, 9.01, 5.05
same fact type: governance_change
same SEC item: 2.02, 9.01
same event type: earnings
This filing
The Company intends to put forth a proposal at the Company’s annual meeting of stockholders to be held in 2026 (the “2026 Annual Meeting”) to amend its Seventh Amended and Restated Certificate of Incorporation in order to declassify its Board of Directors (the “Board”) and provide for the annual election of directors following a phase-in period (the “Proposed Charter Amendment”).
Comparable filing
On May 4, 2026, the Board of Directors of the Company approved an amended and restated Code of Business Conduct and Ethics (the “Code”). The Code was amended to, among other things, update for current compliance best practices, streamline and clarify existing provisions, promote consistency in cross-reference to other of the Company’s polices, and to make other non-substantive administrative and stylistic improvements.
Filing page
SEC filing
BAFN
BayFirst raises $80M in PIPE, reports Q1 loss of $5.7M, names new bank CEO
BayFirst Financial Corp.
April 30, 2026, 7:59 PM ET
other_material
Items 1.01, 3.02, 5.03, 2.02, 5.02, 7.01, 8.01, 9.01
same fact type: governance_change
same SEC item: 2.02, 5.03, 7.01, 9.01
similar materiality
This filing
The Company intends to put forth a proposal at the Company’s annual meeting of stockholders to be held in 2026 (the “2026 Annual Meeting”) to amend its Seventh Amended and Restated Certificate of Incorporation in order to declassify its Board of Directors (the “Board”) and provide for the annual election of directors following a phase-in period (the “Proposed Charter Amendment”).
Comparable filing
On April 28, 2026, the Company filed Articles of Amendment to its Articles of Incorporation with the Florida Division of Corporations creating and authorizing 4,000 shares of Series D Preferred Stock and 4,000 shares of Series E Preferred Stock.
Filing page
SEC filing
Enviri II Corp
New Enviri completes spin-off; starts trading June 2 under NVRI; ~$1.2B revenue, ~$140M EBITDA
Enviri II Corp
June 1, 2026, 5:18 PM ET
m_and_a
Items 1.01, 2.03, 3.03, 5.03, 5.01, 5.02, 5.05, 7.01, 9.01
same fact type: governance_change
same SEC item: 5.03, 7.01, 9.01
similar materiality
This filing
The Company intends to put forth a proposal at the Company’s annual meeting of stockholders to be held in 2026 (the “2026 Annual Meeting”) to amend its Seventh Amended and Restated Certificate of Incorporation in order to declassify its Board of Directors (the “Board”) and provide for the annual election of directors following a phase-in period (the “Proposed Charter Amendment”).
Comparable filing
In connection with the Spin-Off, the Board adopted the Code of Conduct, a copy of which is available on New Enviri’s website at www.enviri.com.
Filing page
SEC filing
APAD
Enhanced Group completes de-SPAC merger with Enhanced Ltd; redemptions of $201.7M
Enhanced Group Inc.
May 8, 2026, 7:59 PM ET
m_and_a
Items 1.01, 2.01, 5.06, 3.02, 9.01, 4.01, 3.01, 3.03, 5.01, 5.02, 5.03, 5.05, 7.01
same fact type: governance_change
same SEC item: 5.03, 7.01, 9.01
similar materiality
This filing
The Company intends to put forth a proposal at the Company’s annual meeting of stockholders to be held in 2026 (the “2026 Annual Meeting”) to amend its Seventh Amended and Restated Certificate of Incorporation in order to declassify its Board of Directors (the “Board”) and provide for the annual election of directors following a phase-in period (the “Proposed Charter Amendment”).
Comparable filing
As a result of the Business Combination, the Company ceased being a shell company
Filing page
SEC filing
DVN
Devon completes all-stock merger with Coterra; combined company retains DVN ticker
DEVON ENERGY CORP/DE
May 7, 2026, 7:59 PM ET
m_and_a
Items 2.01, 5.02, 5.03, 7.01, 9.01
same fact type: governance_change
same SEC item: 5.03, 7.01, 9.01
similar materiality
This filing
The Company intends to put forth a proposal at the Company’s annual meeting of stockholders to be held in 2026 (the “2026 Annual Meeting”) to amend its Seventh Amended and Restated Certificate of Incorporation in order to declassify its Board of Directors (the “Board”) and provide for the annual election of directors following a phase-in period (the “Proposed Charter Amendment”).
Comparable filing
On May 7, 2026, the Company filed an amendment to the Company’s restated certificate of incorporation (the “ Authorized Share Charter Amendment ”), effective as of such date, increasing the number of authorized shares of Company Common Stock from 1,000,000,000 to 2,000,000,000.
Filing page
SEC filing
CHRN
Ekso Bionics completes reverse merger with Applied Digital subsidiary; renames to ChronoScale Corp.
EKSO BIONICS HOLDINGS, INC.
May 5, 2026, 7:59 PM ET
m_and_a
Items 1.01, 2.01, 2.02, 3.02, 3.03, 4.01, 5.01, 5.02, 5.03, 9.01
same fact type: governance_change
same SEC item: 2.02, 5.03, 9.01
similar materiality
This filing
The Company intends to put forth a proposal at the Company’s annual meeting of stockholders to be held in 2026 (the “2026 Annual Meeting”) to amend its Seventh Amended and Restated Certificate of Incorporation in order to declassify its Board of Directors (the “Board”) and provide for the annual election of directors following a phase-in period (the “Proposed Charter Amendment”).
Comparable filing
on May 1, 2026, the Company filed the Second Amended and Restated Articles of Incorporation (the “A&R Articles”) with the Secretary of State of the State of Nevada with a delayed effective date and time of 3:00 a.m. (Eastern Time) on May 5, 2026.
Filing page
SEC filing
SBEV
Splash Beverage receives NYSE delisting notice; shareholders' equity negative $15.3M
SPLASH BEVERAGE GROUP, INC.
May 5, 2026, 7:59 PM ET
regulatory
Items 1.01, 1.02, 3.01, 3.02, 5.03, 7.01, 9.01
same fact type: governance_change
same SEC item: 5.03, 7.01, 9.01
similar materiality
This filing
The Company intends to put forth a proposal at the Company’s annual meeting of stockholders to be held in 2026 (the “2026 Annual Meeting”) to amend its Seventh Amended and Restated Certificate of Incorporation in order to declassify its Board of Directors (the “Board”) and provide for the annual election of directors following a phase-in period (the “Proposed Charter Amendment”).
Comparable filing
On May 4, 2026, the Company filed a Certificate of Withdrawal (the “Withdrawal of Designation”) with the Secretary of State of the State of Nevada and terminated the designation of its Series D Convertible Preferred Stock, par value $0.001 per share (the “Series D”). At the time of filing the Withdrawal of Designation, there were no shares of Series D issued and outstanding. The Withdrawal of Designation became effective upon filing.
Filing page
SEC filing
GYRE
Gyre Therapeutics completes $300M all-stock acquisition of Cullgen; appoints Ying Luo as CEO
GYRE THERAPEUTICS, INC.
May 4, 2026, 7:59 PM ET
m_and_a
Items 2.01, 5.03, 1.01, 3.02, 3.03, 5.02, 7.01, 9.01
same fact type: governance_change
same SEC item: 5.03, 7.01, 9.01
similar materiality
This filing
The Company intends to put forth a proposal at the Company’s annual meeting of stockholders to be held in 2026 (the “2026 Annual Meeting”) to amend its Seventh Amended and Restated Certificate of Incorporation in order to declassify its Board of Directors (the “Board”) and provide for the annual election of directors following a phase-in period (the “Proposed Charter Amendment”).
Comparable filing
The Company has filed with the Secretary of State of the State of Delaware a Certificate of Designation of Preferences, Rights and Limitations of the Company Preferred Stock (the “Certificate of Designation”) in connection with the Merger referenced in Item 1.01 above.
Filing page
SEC filing
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.